AURO-ARIPIPRAZOLE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
17-03-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ARIPIPRAZOLE
Inapatikana kutoka:
AURO PHARMA INC
ATC kanuni:
N05AX12
INN (Jina la Kimataifa):
ARIPIPRAZOLE
Kipimo:
15MG
Dawa fomu:
TABLET
Tungo:
ARIPIPRAZOLE 15MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
30/50/100
Dawa ya aina:
Prescription
Eneo la matibabu:
ATYPICAL ANTIPSYCHOTICS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0152514003; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2018-07-10
Tabia za bidhaa
Page 1 of 71
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AURO-ARIPIPRAZOLE
Aripiprazole Tablets
Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, Oral
House standard
Antipsychotic agent
AURO PHARMA INC.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of initial Authorization:
July 10, 2018
SUBMISSION CONTROL NO: 257093
Date of Revision :
March 17, 2022
Page 2 of 71
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
03/2022
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
.................................................................................................
2
Table of
Contents..........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................
4
1 INDICATIONS
..............................................................................................................................
4
1.1 Pediatrics
....................................................................................................................
4
1.2 Geriatrics
.....................................................................................................................
4
2 CONTRAINDICATIONS
................................................................................................................
5
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
..........................................................................
5
4. DOSAGE AND ADMINISTRATION
..............................................................................................
5
4.1 Dosing Considerations
................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
........................................................... 6
4.3 Administration
............................................................................................................
7
4.4 Reconsti
Soma hati kamili
